JPRN-UMIN000009517
Completed
未知
Clonal deletion of T lymphocytes against host organ by early post-transplant cyclophosphamide: clinical study of GVHD prophylaxis in HLA-haploidentical bone marrow transplantation - HLA-haploidentical BMT using post-transplant CY
Osaka medical center and research institute for maternal and child health0 sites15 target enrollmentDecember 12, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Osaka medical center and research institute for maternal and child health
- Enrollment
- 15
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\. Having a severe complication (NCI\-CTCAE ver3\.0 Grade II or more). 2\. Having an uncontrolled infection. 3\. Physician's decision.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
Induction of neo*antigen specific cytotoxic T cells by autologous tumor lysate-loaded specialized cross*presenting dendritic cells in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy, the NEODOC studyepithelial ovarian cancerhigh grade serous ovarian cancerovarian cancer10038594NL-OMON54480Radboud Universitair Medisch Centrum10
Not yet recruiting
Not Applicable
Detection of unshared-HLA restricted T lymphocytes in HLA mismatched hematopoietic stem cell transplantatioPatients with hematologic disorder who undergoing HLA mismatched hematopoietic stem cell transplantationJPRN-UMIN000044095Hyogo College of Medicine30
Active, not recruiting
Not Applicable
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementpersistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementTherapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]EUCTR2012-003691-40-NLeiden University Medical Center
Completed
Phase 2
Administration of leukemia-reactive donor T cells after allogeneic stem cell transplantation or donor lymphocyte infusion to patients with persistent or relapsed mature B cell neoplasm with blood and/or bone marrow involvementlymfomenleukemialymphoma10024324NL-OMON37016eids Universitair Medisch Centrum4
Recruiting
Not Applicable
Investigation of drug specific cytotoxic T cell in severe cutaneous adverse drug reactioJPRN-UMIN000009708Yokohama City University Graduate School of Medicine10